DossierENTITY

Samsung Biologics

Coverage of Samsung Biologics in the Nexus archive.

Earliest in view: Jul 20 · 02:12 UTCMost recent: Jul 20 · 06:53 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 20 · 06:53 UTCFINANCIAL TIMES WORLD
Samsung Biologics buys Swiss peptide maker for $1.8bn
Samsung Biologics has acquired a Swiss peptide manufacturer for $1.8 billion. This acquisition exemplifies South Korean companies expanding abroad through acquisitions.
BUSINESSJul 20 · 02:12 UTCCNBC TOP
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics has acquired PolyPeptide Group in a $1.8 billion all-cash deal. The transaction is valued at 2.7 trillion won.